Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 0

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 0
---
TABLE OF CONTENTS

<div align='center'>UNITED STATES SECURITIES AND EXCHANGE COMMISSION 
 Washington, D.C. 20549</div>

#### FORM 6-K
<div align='center'>Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under 
 the Securities Exchange Act of 1934

For the month of September 2025

Commission File Number: 001-11960</div>

#### AstraZeneca PLC
<div align='center'>1 Francis Crick Avenue 
 Cambridge Biomedical Campus 
 Cambridge CB2 0AA 
 United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40- F:

Form 20-F ☒ Form 40-F ☐</div>

TABLE OF CONTENTS

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you are recommended to seek your own personal financial advice immediately from an appropriately authorised stockbroker, bank manager, solicitor, accountant or other independent financial adviser who, if you are taking advice in the United Kingdom (“UK”), is duly authorised by the Financial Services and Markets Act 2000 (“FSMA”), or, if you are not resident in the UK, from another appropriately authorised independent financial adviser in your own jurisdiction.

If you sell or have sold or otherwise transferred all of your shares in AstraZeneca PLC (“

#### AstraZeneca
”), please send this document and any accompanying documents or forms (other than documents or forms personalised to you) as soon as possible to the purchaser or transferee or to the stockbroker, bank or other agent through whom you sell or have sold or transferred your shares for delivery to the purchaser or transferee. If you have sold or otherwise transferred only part of your holding of AstraZeneca Shares (as defined below), please consult the bank, stockbroker or other agent through whom the sale or transfer was effected as to the action you should take.

This document is not a prospectus or prospectus-equivalent document and it does not constitute or form part of any offer or invitation to purchase, acquire, subscribe for, sell, dispose of or issue, or any solicitation of any offer to purchase, acquire, subscribe for, sell or dispose of, any security, including any AstraZeneca Shares.

#### AstraZeneca PLC